News Updates
Scope

Tue, May 26, 2026

1 updates
OLMA
7:00 AM

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

Study to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 First clinical collaboration for OP-3136; results to inform combination strategy in metastatic prostate cancer setting SAN FRANCISCO, May 26, 2026

Presentation / Abstract • Phase 1ASCO poster presentation Sat, May 30, 2026olema.com

Thu, May 21, 2026

1 updates
OLMA
5:00 PM

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor types Data support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy

Presentation / Abstract • Phase 1Poster presentation Sat, May 30, 2026, 1:30 PM CTolema.com

Tue, May 19, 2026

1 updates
OLMA
4:30 PM

Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that

olema.com

Tue, May 12, 2026

1 updates
OLMA
7:00 AM

Olema Oncology Reports First Quarter 2026 Financial and Operating Results

Top-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patients First clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securities SAN

Presentation / Abstract • Phase 1ASCO abstract release Fri, May 29, 2026, 5:00 PM ETolema.com

Mon, May 4, 2026

1 updates

Wed, Apr 29, 2026

1 updates
OLMA
4:01 PM

Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors

SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the

olema.com

Tue, Apr 21, 2026

1 updates

Fri, Apr 17, 2026

1 updates

Thu, Apr 2, 2026

1 updates

Tue, Mar 17, 2026

1 updates

Mon, Mar 16, 2026

1 updates

Tue, Mar 3, 2026

1 updates